Hypertension. Essential (primary) hypertension
Conditions
Interventions
Intervention 1: Intervention group: Spironolactone, 25 mg oral tablet, one tablet daily for one month. Intervention 2: Control group: placebo, oral tablet, one tablet daily for one month.
Treatment - Drugs
Placebo
Intervention group: Spironolactone, 25 mg oral tablet, one tablet daily for one month
Control group: placebo, oral tablet, one tablet daily for one month
Sponsors
Shiraz University of Midical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion crireria: systolic blood pressure more than 135 mmhg; diastolic blood pressure more than 85 mmhg Exclusion criteria: serum creatinine more than 2 mg/dl; serum potassium more than 5 meq/l; renal or other endocrine diseases; diabetes
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Systolic blood pressure. Timepoint: Before intervention and 1 month after intervention. Method of measurement: Ambulatory 24 hour blood pressure holter monitoring.;Diastolic blood pressure. Timepoint: Before intervention and 1 month after intervention. Method of measurement: Ambulatory 24 hour blood pressure holter monitoring. | — |
Secondary
| Measure | Time frame |
|---|---|
| Level of serum potassium. Timepoint: Before Intervention and One Month After Intervention. Method of measurement: Biochemical Measurements on Blood Sample. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmirabbas Sadeghi
Shiraz University of Medical Sciences
Outcome results
None listed